Top Stories
Counsel will join CMS's ACCESS model in early 2027 to provide care to Medicare patients with hypertension, obesity, hyperlipidaemia and prediabetes.
Orbis' nGen platform combines generative AI and high-throughput synthesis to generate macrocycle compounds that are orally bioavailable.
MMI is the third company backed under the partners' €150 million co-investment initiative in less than a year.
In an international study, PANXEON was highly sensitive in detecting stage 1 and 2 pancreatic cancer and also spotted high-grade dysplasia.
The Danish pharma will use Anthropic models and its Claude Science AI workbench to advance scientific reasoning for R&D.
Conference News
Interim data show high adherence and usability for remote, multimodal brain monitoring in borderline personality disorder and therapy-resistant depression, and a two-minute digital cognitive task perf...
ZEISS' new multimodal solution combines automated OCT and fundus imaging to support simplified and efficient retinal assessment across a broader range of eye care practices.JENA, Germany, Sept. 17, 20...
These findings support the potential of MammaTyper® LRP as a locally available low cost molecular pre-screen for identifying patients having an Oncotype DX® RS ≤25 who are at low recurrence risk.”— Ri...
DALLAS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more...
SAN DIEGO--(BUSINESS WIRE)--ClearNote Health, a company dedicated to improving early detection and monitoring for some of the deadliest cancers, today announced it will present new data for its Avante...
